NCT04220021View on ClinicalTrials.gov

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

August 26, 2024

Study Completion Date

June 30, 2026

Conditions
C9orf72 Amyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia
Interventions
DRUG

Metformin

Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.

Trial Locations (1)

32610

UF Health at the University of Florida, Gainesville

All Listed Sponsors
collaborator

ALS Association

OTHER

lead

University of Florida

OTHER